State Initiatives to Legalize Schedule 1 Drugs
UNITED STATES NUCLEAR REGULATORY COMMISSION OFFICE OF NUCLEAR MATERIAL SAFETY AND SAFEGUARDS OFFICE OF NUCLEAR REACTOR REGULATION WASHINGTON, DC 20555-0001 January 17, 1997 NRC ADMINISTRATIVE LETTER NO. 97-01: State Initiatives to legalize Schedule 1 drugs Addressees All holders of operating licenses or construction permits for nuclear power reactors and all licensees authorized to possess or transport Category I nuclear material. Purpose The U.S. Nuclear Regulatory Commission (NRC) is issuing this administrative letter to remind addressees that the requirements of Part 26 of Title 10 of the Code of Federal Regulations (10 CFR Part 26) remain in effect, even where State law attempts to legalize the use of Schedule 1 drugs. It is expected that recipients will review this administrative letter and take whatever actions are considered appropriate to ensure continued compliance with Commission rules regarding the use of controlled substances under Federal law. This administrative letter does not create any new or changed NRC requirements or staff positions; no specific action or written response is required. Background On November 5, 1996, California voters passed an initiative (Proposition 215) authorizing physicians to recommend the use of marijuana for the treatment of "any [other] illness for which marijuana provides relief." It does not require a physician's prescription or other written record of the recommendation. In Arizona, voters passed an initiative (Proposition 200) allowing the medical use of all controlled substances in Schedule I of the Controlled Substance Act, not just marijuana. It requires a physician's prescription, following a second opinion from another physician. Licensees for nuclear power plants may be affected because outage workers are highly mobile and may come from a State that permits the use of Schedule I drugs contrary to Federal law. 9701170091. AL 97-01 January 17, 1997 Page 2 of 2 Discussion Rules of the NRC, which are promulgated for radiation safety in nuclear power plants and Category I licensees under the Atomic Energy Act of 1954, as amended, preempt State law, such as California Proposition 215 and Arizona Proposition 200. Accordingly, the California and Arizona initiatives do not affect the application of 10 CFR Part 26 or licensee programs that implement those NRC requirements. This also applies to any other current or future State laws that permit the use of controlled substances other than as permitted under Federal law. Addressees are also reminded that licensee programs established to satisfy 10 CFR Part 26 require workers to report to the licensee any condition, including the use of any medication (whether prescribed or not), that may result in their not being fit to safely and competently perform their duties. This administrative letter requires no specific action or written response. Should any licensee conclude that it needs to revise its written policy to address these matters, persons covered by the policy should be informed of the change in accordance with 10 CFR 26.21. If you have any questions about this matter, please contact one of the technical contacts listed below or the appropriate NRC regional office. signed by signed by Elizabeth Q. Ten Eyck, Director Thomas T. Martin, Director Division of Fuel Cycle Safety and Division of Reactor Program Management Safeguards Office of Nuclear Reactor Regulation Office of Nuclear Material Safety and Safeguards Contacts: Reactor Licensees: Loren Bush, NRR (301) 415-2944 E-mail: llb@nrc.gov Fuel Cycle Licensees: Brett Miller, NMSS (301) 415-8152 E-mail: btm@nrc.gov
Page Last Reviewed/Updated Tuesday, March 09, 2021
Page Last Reviewed/Updated Tuesday, March 09, 2021